Blood-Contacting Biomaterials: <i>In Vitro</i> Evaluation of the Hemocompatibility.
Weber M, Steinle H, Golombek S, Hann L, Schlensak C, Wendel HP, Avci-Adali M. · 2018
Read Blood-Contacting Biomaterials: <i>In Vitro</i> Evaluation of the Hemocompatibility. by Weber M, Steinle H, Golombek S, Hann L, Schlensak C, Wendel HP, Avci-Adali M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6054932.txt.
Introduction
Weber and co-authors review lab testing of materials that touch blood. Their article appeared in Frontiers in Bioengineering and Biotechnology. Devices like stents, valves, and catheters meet blood directly. A bad reaction can trigger clots or inflammation. Testing must happen before clinical use.
Rules in an international standard guide the testing. Materials sit with fresh human blood in lab models. Models can be still, shaken, or flowing. Teams then measure cell damage and counts. Platelet, clotting, and complement activation are checked. Surfaces are inspected for stuck cells and proteins. Clot and fibrin formation on surfaces is scored. Readers get a full checklist for judging blood safety of new materials.
Catalog record
| CREATOR | Weber M, Steinle H, Golombek S, Hann L, Schlensak C, Wendel HP, Avci-Adali M. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Blood-Contacting Biomaterials: In Vitro Evaluation of the Hemocompatibility By Marbod Weber, Heidrun Steinle, Sonia Golombek, Ludmilla Hann, Christian Schlensak, Hans P Wendel, Meltem Avci-Adali Published in: Frontiers in Bioengineering and Biotechnology DOI: 10.3389/fbioe.2018.00099 ABSTRACT Abstract Hemocompatibility of blood-contacting biomaterials is one of the most important criteria for their successful in vivo applicability. Thus, extensive in vitro analyses according to ISO 10993-4 are required prior to clinical applications. In this review, we summarize essential aspects regarding the evaluation of the hemocompatibility of biomaterials and the required in vitro analyses for determining the blood compatibility. Static, agitated, or shear flow models are used to perform hemocompatibility studies. Before and after the incubation of the test material with fresh human blood, hemolysis, cell counts, and the activation of platelets, leukocytes, coagulation and complement system are analyzed. Furthermore, the surface of biomaterials are evaluated concerning attachment of blood cells, adsorption of proteins, and generation of thrombus and fibrin networks. Keywords: hemocompatibility, blood contact, biomaterials, coagulation, complement system INTRODUCTION Hemocompatibility is one of the major criteria, which limit the clinical applicability of blood-contacting biomaterials. These materials come in close contact with blood, which is a complex “organ,” comprising of 55% plasma, 44% erythrocytes, and 1% leukocytes and platelets. Thus, adverse interactions between newly developed materials and blood should be extensively analyzed to prevent activation and destruction of blood components. The initially adsorbed protein layer on the biomaterial surface mainly triggers the adverse reactions, such as the activation of coagulation via intrinsic pathway, the activation of leukocytes, which results in inflammation, and the adhesion and activation of platelets (Liu et al., 2014). As a result, the number of blood cells can decrease and a thrombus can be formed. Thus, the applied blood-contacting biomaterials should not adversely interact with any blood components and activate or destruct blood components. Erythrocytes are the most abundant blood cells with 4–6 × 106 cells/μl and they are important for the transport of oxygen (O2) from the lung to all tissues and cells and carbon dioxide (CO2) from tissues back to the lung. Since erythrocytes are the most rigid cells in the blood, they are sensitive to rupture and hemolysis due to shear stress and changes in osmotic pressure. Blood platelets are the smallest (1–3 μm) and the second abundant cell type in the blood with 1.5–3.5 × 105 cells/μl, which can rapidly recognize foreign surfaces and initiate blood coagulation. Furthermore, human blood contains 4.3–10 × 103 leukocytes/μl, such as granulocytes, lymphocytes, monocytes, dendritic and natural killer cells. Monocytes account for 1–6% of all leukocytes and neutrophil granulocytes are the most abundant leukocytes in the blood, comprising 50–70% of all leukocytes. These immune cells are belonging to the innate immune system and they can be rapidly activated upon recognition of a foreign invader such as a pathogen or a foreign material. Furthermore, blood plasma contains high amounts of plasma proteins, such as albumin, coagulation factors, and immunoglobulins. Catheters, guidewires, dialyzer, oxygenators (artificial lungs), heart-supporting systems, cardiac pacemaker, vascular grafts, stents, heart valves, micro-, and nanoparticles are widely used medical devices and materials coming in direct contact with blood. Prior to clinical application, the hemocompatibility of blood-contacting medical materials have to be analyzed and therefore, a guidance is developed by the International Organization for Standardization (ISO 10993-4) (International Organization for Standardization, 2000). According this guideline, five different categories, thrombosis, coagulation, platelets, hematology, and immunology (complement system and leukocytes), are indicated for hemocompatibility evaluation. The devices are divided into three categories concerning blood contact: (1) Externally communicating devices with indirect blood contact, e.g., cannulas and blood collection sets; (2) Externally communicating devices with direct blood contact, e.g., catheters and hemodialysis equipment; (3) Implant devices, e.g., heart valves, stents, and vascular grafts. So far, several studies were performed according ISO-10993-4 to evaluate various blood contacting devices and materials, such as stents (Sinn et al., 2011; Stang et al., 2014), catheters with a noble metal alloy coating (Vafa Homann et al., 2016), poly(2-dimethylamino-ethylmethacrylate) (PDMAEMA) (Cerda-Cristerna et al., 2011), and DNA hydrogels (Stoll et al., 2017). To perform hemocompatibility analysis, static, agitated, or shear flow in vitro models are used for the incubation of blood with the biomaterial. Before and after the incubation of biomaterials with fresh human blood, the activation markers regarding hemocompatibility are analyzed (Figure 1). [Figure: Schematic representation of the procedure for the evaluation of the hemocompatibility of biomaterials. First, fresh human blood is collected and anticoagulated with low dose heparin. Thereafter, the test material is incubated at 37°C using static, agitated, or dynamic test models with the blood. The activation markers in the blood are analyzed before and after the incubation with the test material. Furthermore, the surface of the biomaterial is analyzed to determine the interaction of blood cells and proteins with the biomaterial surface.] INCUBATION OF BIOMATERIALS WITH HUMAN BLOOD Using fresh human blood and adequate in vitro models, the hemocompatibility of blood-contacting biomaterials can be studied accurately. Compared to in vivo animal models, in vitro models allow the analysis under well controllable conditions such as blood flow, anticoagulation and eliminate disturbing factors related to flow obstruction, surgery, and tissue effects (van Oeveren, 2013). Furthermore, the blood contact is more intense and products generated due to reaction of the blood components to the biomaterial are not cleared. Moreover, using in vitro models, different devices can be analyzed under the same conditions, which enable the direct comparison of outcomes. Thereby, positive controls, which show a poor hemocompatibility, such as glass (Ferrer et al., 2013), devices or biomaterials, which are already on the market with a comparable surface area, and negative controls without test material should be simultaneously tested to be able to evaluate the hemocompatibility. The quality of collected blood is extremely important to enable standardized hemocompatibility analysis. The in vitro analysis should be performed with fresh blood from healthy subjects (Blok et al., 2016). Blok et al. demonstrated that the stationary storage of blood over 4 h at room temperature affects the platelet function and activity of leukocytes. Thus, experiments should be started within 4 h after the blood collection. However, the faster the experiments are started, the better it is. Peripheral blood should be collected from healthy non-smoker, non-pregnant subjects free of medication (particularly drugs affecting the hemostasis, such as aspirin, oral contraceptives, and nonsteroidal anti-inflammatory drugs). Moreover, atraumatic blood collection by minimizing venostasis during blood withdrawal and the use of 21-gauge needles is required to minimize activation of platelets and the coagulation cascade during collection (Braune et al., 2013). Furthermore, prior to starting hemocompatibility analyses, unreacted monomers, intermediate- or by-products, solvents, and unwanted chemical residues should be removed by appropriate washing and cleaning procedures from generated biomaterials to eliminate an unwanted influence on blood components. Depending on biomaterial, device, and production technique, different washing and cleaning procedures with different solutions are required, for example ethanol can be removed by evaporation or washing with PBS (Punet et al., 2015), NaCl, or water and unreacted methacrylic anhydride and by-products can be eliminated by dialysis (Xiao et al., 2011; Camci-Unal et al., 2013). Additionally, endotoxin content should be determined to exclude material-unrelated activation of platelets and blood cells due to presence of endotoxins (Watanabe et al., 2003; Kälsch et al., 2007; Schrottmaier